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Abstract The results from randomized clinical trials are
often adopted slowly. This practice potentially prevents
many people from benefiting from more effective care.
Provide a framework for analyzing clinical trial results to
determine whether and when early adoption of novel
interventions is appropriate. The framework includes the
evaluation of three components: confidence in trial results,
impact of early, and late adoption if trial results are
reversed or sustained. The adverse impact of early adop-
tion, and the opportunity cost of late adoption are deter-
mined using Markov modeling to simulate the impact of
early and late adoption in terms of quality of life years and
resources gained or lost. We applied the framework to the
TARGIT-A randomized clinical trial comparing intraop-
erative radiation (IORT) to standard external beam radia-
tion (EBRT) and considered these results in the context of
trials comparing endocrine therapy with and without radi-
ation therapy in postmenopausal women. Confidence in the
TARGIT-A trial 4 year results is high because the peak
hazard for local recurrence in the trial is between 2 and
3 years. This is consistent with most trials, and no second
peak has been observed in similar patient populations,
suggesting that the TARGIT-A trial results are stable. The
interventions offer approximately equivalent life expec-
tancy. If IORT local recurrences rate were as high as 10 %
at 10 years (which is higher than expected), we would
project only 0.002 fewer expected life years (less than
1 day) compared to EBRT if IORT is adopted early.
However, there is a $1.7 billion opportunity cost of waiting
an additional 5 years to adopt IORT in low risk, hormone-
receptor-positive, postmenopausal women. EBRT costs an
additional $1467 in indirect costs per patient. Applying an
evaluative framework for the adoption of clinical trial
results to the TARGIT-A IORT therapy trial results in the
assessment that the trial results are stable, early adoption
would lead to minimal adverse impact, and substantially
less resource use. Both IORT and no radiation are rea-
sonable strategies to adopt.
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Introduction
Clinical adoption should occur when high-level randomized
data clearly show the efficacy of one treatment against
another, without serious adverse effects. However, several
factors other than evidence regarding these outcomes influ-
ence the adoption of new findings from clinical trials. For
example, when less treatment is shown to have an equivalent
outcome, change in practice is highly variable. It is typically
easier to adopt or add new agents or treatments, but can be
hard to abandon what is seen as standard treatment.
In the United States, new business for physicians, hospi-
tals, and manufacturers that result from a positive trial often
helps drive adoption. However, when new approaches
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disrupt the routine of practice, or when interventions reduce
the use of particular services, there may be less incentive for
early adoption [1]. Reasons for slow adoption include
financial disincentive, disruption of practice routines, resis-
tance to change, fear of abandoning a standard treatment, and
skepticism about trial results [1].
The question of how to approach patients with early stage,
favorable risk breast cancer illustrates the complexity of for-
ces influencing decision making with regard to the adoption of
new approaches. Whole-breast external beam radiotherapy
(EBRT) remains the standard of care following breast-con-
serving surgery. However, multi-dose partial breast radiation
is increasingly offered as an alternative for eligible women.
Emerging technologies have provided impetus for shifts in
radiation approaches despite lack of randomized clinical trial
data for these devices [2]. The frequency of brachytherapy use
increased from*1 % in 2001 to 10 % in 2006, despite con-
cerns about long-term efficacy [3].
Meanwhile, the finding from a randomized trial (CAL-
GB 9343) that older women with hormone-receptor-posi-
tive breast cancer could be effectively treated with
tamoxifen without radiation therapy have yet to be adopted
into clinical practice [4]. The results demonstrated that
with or without radiation, distant recurrence, breast cancer
mortality, and mastectomy rates are the same and very low
in the two arms [5]. Despite these results with more than
10 years of follow-up, and corroborating evidence from a
similar Canadian trial in all postmenopausal women, [6]
radiation is rarely omitted and post-lumpectomy radiation
is considered a quality measure by the American College of
Surgeons for older women [7]. Fear of omitting therapy
and being less aggressive often makes both physicians and
patients uncomfortable, even in the face of supporting
evidence to the contrary. There is a cultural bias which
dictates that more aggressive treatment for cancer is better,
and this bias colludes with the fear of malpractice and
financial rewards to encourage intervention.
With this as prelude, it is not surprising that when the
results of the international randomized trial comparing a
single intraoperative radiation (IORT) using low-energy
photons delivered by the TARGIT device were published
in 2010, there was a great deal of criticism and arguments
that it was too early to adopt the findings [8]. Indeed, early
adoption of technology that turns out to be inferior to the
status quo can be harmful, but late adoption of technology
that turns out to be equivalent or superior to the status quo
can be a missed opportunity that also harms individuals and
society. Clearly, a rational approach is needed to put early
trial results in perspective and facilitate adoption decisions.
We propose a decision framework for the adoption of
clinical trial results that includes three components. First,
we ex amine the level of confidence we have in the trial
results, second, we predict the impact of early adoption of
trial results, and third, we predict the impact of late
adoption of those trial results. Predicted impact is measured
through life expectancy, quality-adjusted life years (QA-
LYs), and cost. We apply the proposed framework to the
example of the TARGIT-A intraoperative radiotherapy
trial to illustrate this approach in the hopes of providing a
better platform for decision making for the medical
community.
Methods
The adoption framework (shown in Fig. 1) relies on predictive
modeling, which can aid policy decisions by projecting pos-
sible outcomes. Within this framework, sensitivity analyses
are used to determine the impact of initial assumptions and
how possible changes in data might impact conclusions from
clinical trials.
The example
The TARGIT-A trial randomized women with invasive
hormone-positive ductal breast carcinoma (\3.5 cm)
undergoing breast-conserving surgery to receive either one-
time targeted IORT (TARGIT) or whole-breast EBRT [9].
In a risk-adapted design, women with invasive lobular,
hormone-receptor-negative, or positive nodes received
EBRT in addition to TARGIT. Early results were published
in The Lancet in 2010: the Kaplan–Meier estimate of local
recurrence in the conserved breast at 4 years was 1.20 %
(95 % CI 0.3–2.71) and 0.95 % (0.39–2.31) for TARGIT
and EBRT arms, respectively [9]. The IORT treatment was
deemed not inferior to EBRT as the IORT recurrence rate
was within the prospectively defined non-inferiority margin
of 2.5 %. (difference between groups 0.25 %,–1.04 to 1.54;
p = 0.41). Toxicity (Radiation Therapy Oncology Group
grade 3) was lower in the TARGIT arm. The updated
results 2 years later show a 2 % difference overall. When
TARGIT is applied at the time of lumpectomy as a single
surgery, there is no difference in the local recurrence rates
when compared to EBRT [10].
The framework examines the following three questions:
(1) What is the likelihood that the trial results are
stable?
Analyzing the hazards for disease recurrence or pro-
gression over time to determine if the hazard for recurrence
has peaked is one way to generate confidence in whether
the trial results will change. The trial in question should
also be compared to results from other published trials with
similar patient populations, to determine consistency of
results. A more rigorous alternative is to predict the
Bayesian likelihood or predictive probability that the trial
results will change.
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(2) What is the impact of early adoption?
Predictive modeling was used to quantify the negative
impact of adopting too early and the possible changes in
results—such as an increase in toxicity or recurrence rate—
on life expectancy, QALYs, and cost. Sensitivity analyses
were conducted to predict outcomes over a range of pos-
sible costs, probabilities, and utilities.
(3) What is the impact of late adoption?
Predictive modeling was also used to determine the cost
associated with delaying the adoption of a less expensive
treatment. Opportunity cost to an individual may include
lost wages, lack of convenience, or decreased life expec-
tancy or QALYs. Societal costs include the aggregate cost
of the more expensive treatments during the period that the
adoption was delayed.
We applied the adoption framework to the published
4-year results of the international TARGIT-A to illustrate
how the proposed framework can be used to inform policy.
We used Markov modeling to simulate life expectancy,
QALYs, and costs as a cohort of individuals’ transitions
between expected health states over a relevant time period
[11, 12] The model uses 2011 Medicare reimbursement
rates, discounted at 3 %, and published utility values [13].
Results
(1) Confidence in the long-term durability of early trial
results
The peak of local recurrence occurred at 3 years in the
TARGIT-A trial and the annual hazards for recurrence in
both arms were quite low [9]. The hazards for local
recurrence were 0.0, 0.3, 1.2, and 0 versus 0.0, 0.15, 1.1,
and 0.0 for IORT and EBRT for years 1–4, respectively.
More than 1,500 women had a median follow-up of
3 years, and more than 800 women had a median follow-up
of 4 years. Comparing to trials with similar postmeno-
pausal populations and longer follow-up periods, we see
peak hazards at similar times. The adjuvant arimidex ver-
sus tamoxifen versus combination study, as well as the
early breast cancer trials meta-analysis also show early
peak hazards for local risk of recurrence (LRR) between 2
and 3 years and within 2 years, respectively. No second
LRR peaks are seen within the 10-year follow-up period
[14, 15]. In another IORT trial of 1,200 patients random-
ized to radiation versus no radiation (ELIOT), median local
recurrence occurred at 26 months [16]. The British Asso-
ciation of Surgical Oncology II trial, which randomized
1135 low-risk patients to XRT vs. tamoxifen using a 2 9 2
design, found that either EBRT or tamoxifen was associ-
ated with a 10-year survival of 96 %, both 100 %, and
none 87 %. The annual % local recurrence rate was 2.1,
0.7, 0.8, and 0.0 for no treatment, XRT alone, tamoxifen
alone, or both, respectively [1]. Therefore, for postmeno-
pausal women with low risk hormone-positive cancers, the
local recurrence rates seen in the TARGIT-A trial are
highly likely to remain low.
(2) Potential adverse impact of early adoption
The adverse impacts of early adoption were predicted
using a Markov model to simulate the outcomes (life
expectancy, QALYs, and cost) of the three different treat-
ment options, IORT, EBRT, or no radiotherapy (tamoxifen
only). The 4-year TARGIT-A results were used as baseline
inputs for the model and then varied. We used the ‘‘tamox-
ifen only’’ results from the tamoxifen alone versus tamoxifen
plus EBRT to establish a 10-year LRR upper bound [6] to be
used in the sensitivity analyses in our Markov model as the
vast majority of patients with hormone positive disease
receive some form of endocrine therapy (either tamoxifen or
aromatase inhibitors). Toxicities were included as previ-
ously described [13]. Mortality rates were assumed to be the
same in the two treatment arms as has been observed from
trials of XRT versus none with a similar population of
patients (node-negative and hormone-receptor-positive) [5,
6, 17].
Life expectancy
At the projected IORT LRR (3 % over 10 years), the two
treatments are essentially equivalent in terms of life
Fig. 1 Overview of the
adoption framework—the
decision of whether or not to
adopt trial results is based on
consideration of the confidence
in the trial results and an
assessment of the impact of
early versus late adoption of the
results according to life
expectancy, QALYs, and cost
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expectancy, with IORT resulting in an expected 0.0002
fewer life years (less than 2 h) than EBRT. The LRR was
varied well beyond the published annual rate from the
TARGIT-A trial in sensitivity analysis [9]. Even at the
highest clinically relevant 10-year LRR of 10 % (the pre-
dicted difference in LRR without any radiation), the impact
on life expectancy would be just 0.002 fewer life years
(less than 1 day) with IORT compared to EBRT (Fig. 2).
This assumes all patients receive hormonal therapy.
Quality of life impact
Side effects occurred less frequently with the single intra-
operative treatment, Radiation Therapy Oncology Group
grade 3) events were lower in the IORT group than in the
EBRT group (0.5 and 2.1 %, p = 0.002). This was not
incorporated into the analysis, but favors application of
IORT given that there is no adverse impact on life
expectancy.
(3) Impact of late adoption
Cost to society
To calculate the opportunity cost to society of delaying
adoption of trial results by an additional 5 years, we first
determined the magnitude of the population for whom this
technology would be applicable. We estimated that 70,136
women are eligible each year for IORT or no RT (N0,
grades 1 and 2 ductal cancers in postmenopausal women
[50 years old) from SEER and US Census Bureau data
(Table 1).
Early adoption of the TARGIT-A trial results after the
report of the 4-year outcomes as opposed to waiting the
10 years was calculated to save the health care system $1.7
billion. If the same women avoided RT altogether the
savings are expected to be $3.2 billion.
In calculating the incremental cost-effectiveness ratios
(ICERs) for each of the three treatment arms (EBRT,
IORT, and no radiation therapy), we found that EBRT was
the most costly option, offered the least QALYs, and was,
therefore, dominated by both IORT and the absence of any
radiation therapy. The ICER for the IORT compared to no
radiation therapy was $10,186/QALY.
Cost to patient:
Patients face numerous indirect costs that may have a
significant impact on their daily lives. Instead of the one-
time intraoperative dose of radiotherapy with IORT,
patients who receive EBRT must travel to a radiation
therapy facility every day for upto 3–6 weeks. We incor-
porated these additional burdens, including miles traveled
and wages lost, as indirect costs in the Markov model for
the EBRT [13]. As estimated from the literature, total
treatment time (travel, parking, and treatment) was mod-
eled to be 2 h per treatment. The average hourly 55-year-
old female wage ($13.68) was taken from the US Bureau of
Labor Statistics and adjusted to 2011 US dollars. The travel
distance was estimated to be 20 miles at 19 cents/mile.
Fig. 2 Predicted life expectancy based on a possible range of LRR
values for IORT (assuming no change in LRR for EBRT). LRR for
‘‘No RT’’ is assumed to be 10 % at 12 years based on the CALGB
9343. So when the LRR for IORT is extended beyond 10 %, it
appears that IORT life expectancy is worse than ‘‘no RT’’, but that is
artificial. This figure demonstrates that the impact of early adoption,
even if the results change significantly (5 9 more than expected to
10 %), is negligible. The 10-year IORT LRR projected from the
results published in 2010 and 2012 are 3 and 6 %, respectively
Table 1 Projected incidence of breast cancer in the US in women of
all races, limited to grade 1 and 2, node-negative













85? years 43.1 4,974
Total 70,136
For each age group, the percent of patients meeting these criteria is
shown, and the absolute number of women is projected based on
annual incidence of breast cancer in the United States (SEER
2003–2007)
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Per-day costs were added for 28 treatments for 5 weeks of
EBRT following IORT and 33 treatments for the 6-week
EBRT regimen. The total indirect cost to a patient of
undergoing EBRT instead of IORT or no radiation therapy
was $1467 (this amount was included in the $1.7 billion
stated above).
Summary of results (Fig. 3)
Given that the peak hazard for local recurrence is early
in all postmenopausal women, we would not expect the
result of the TARGIT-A trial to change. The results of
CALGB-9343 are now well past 10 years, and the 5-year
results indeed predicted the 10.5-year results. IORT is not
expected to be associated with an adverse impact on life
expectancy, even in the highly unlikely event that the long-
term results did change. There would be no increase and
likely a decrease in toxicity. In contrast, continuing with
EBRT results in a $1.7 billion opportunity cost compared
with early adoption of the TARGIT-A trial results.
Discussion
Decision making in low-risk patients is often more com-
plicated than for those with high risk. The reason is that the
benefit from an intervention and its side effects may not
outweigh the risk of the disease. Thus, a postmenopausal
woman with a favorable risk hormone-receptor-positive
breast cancer has several options after breast conservation,
including hypofractionated EBRT, IORT, or no radiation,
which are all supported by the literature as at least equiv-
alent, if not superior, strategies to EBRT [18, 19]. And yet,
trial results have not significantly influenced practice in the
United States. When the CALGB 9343 results were pre-
sented in 2002, they met a similar reaction to the results of
the TARGIT-A results in 2010. Many demanded 10 years
of data prior to adoption.
In the CALGB 9343 trial, the findings reported at
5 years were predictive of the results at 10.5 years (see
Table 2). In June of 2005, CALGB 9343 was presented,
showing equal impact on life expectancy of EBRT versus
no radiation in settings of hormone-receptor-positive
women age 70 or older. In December of 2010, the CALGB
9343 10.5-year results were published but the trial results
have yet to be adopted, suggesting that the factors other
than evidence and patient benefit are driving practice
changes. This suggest that we need more rigorous methods
of how we evaluate trial results and how we choose to use
them. The results of the potential harm and opportunity
cost from failure to adopt early are striking and suggest that
we should be doing less for women with lower risk tumors.
Over time, the local recurrence rates have been coming
down from the original reported risk of 10 % after IORT.
Recent studies show rates largely less than 5 % and even
lower when endocrine therapy is used. Data from 4 trials
with populations of similar biology (postmenopausal
women with node-negative, hormone-receptor-positive,
early stage breast cancer) are shown in Table 2. Local
recurrence rates are low even in the less intensive EBRT
arms or the complete absence of radiation. Fyles et al.
found that women over 50 in the low risk group—immu-
nohistochemistry subtype luminal A—had a local recur-
rence of 4.9 % at 10 years. Thus the IORT results, which
show a very low LRR, are consistent with other modern
trial results. It should be noted that there was no difference
in metastatic rates or overall survival for any of the trial
arms.
We did not account for the cost of purchasing the IORT
equipment, which would be an added cost if the LRR
Fig. 3 Adoption framework:
summary of results
Breast Cancer Res Treat (2014) 144:371–378 375
123
eventually is shown to be equivalent to no radiation.
Equipment, however, can be leased and not purchased and
is included in the cost of IORT. We also did not have
the ability to assess the utility of avoiding 3–6 weeks of
daily radiation, and therefore, likely underestimated the
improvement in QALYs with IORT.
The 2012 TARGIT-A trial update shows a very small
but statistically significant increase in non-breast cancer
(cardiac) mortality for EBRT compared to IORT [10]. Our
analysis assumes that IORT and EBRT are expected to be
equivalent in terms of life expectancy; an improvement in
expected mortality for either treatment will shift the results
to favor that strategy. If over time, the small mortality
benefit in favor of IORT persists, the IORT would be
favored on the basis of mortality benefit as well.
Breast cancer is now recognized as being comprised of
several distinct diseases. One of the reasons that the LRR
appears to be so much lower is likely due to the impact of
mammography screening and the identification of tumors
that are biologically more indolent [20–22]. The results
from older trials where there was a 40 % LRR in the
absence of radiation applied to younger women and tumors
with more aggressive biology [23]. Thus, reframing risk
and options must occur as we have the ability to better
characterize the biology of newly diagnosed breast cancers
[24] and offer better options for women with low risk
disease, and where recurrence is not life threatening.
The risk for distant breast cancer recurrence for hor-
mone-receptor-positive women does extend over a 20-year
period of time [25]. This well-known fact leads to an
erroneous conclusion that the TARGIT-A study results
were ‘‘too early’’ to adopt. The statisticians were confident
in the TARGIT-A results because data clearly show that
the peak hazard rate for local recurrence is early, and is
then low and stable, thus the overall conclusions are
extremely unlikely to change. This assumption was further
validated by the recent update of the TARGIT-A results,
where the conclusions of non-inferiority remain unchanged
for patients treated at the time of initial resection [10].
The demonstration that less aggressive interventions are
equally effective for women with lower risk tumors is a
critical breakthrough for women and a major advance in
our ability to tailor treatments for women according to the
biology of their tumors. If we can safely accomplish the
same goal (preventing cancer recurrence) in a much more
efficient, less invasive, and less personally time-consuming
manner for women, the physician community should be the
first to embrace this therapy. The complaint about IORT
seems to be that the data are immature; however, clinical
practitioners can switch to IORT and watch the data
Table 2 The results of local recurrence rates at 5, 10, and 10.5 years of follow-up in recent clinical trials






TARGIT-A 2010 2000–2012 2,232 IORT 1.20a N.A. N.A.
EBRT 0.95a
Studies comparing XRT versus NO XRT
CALGB C9343 Hughes et al. [5] 1994–1999 636 Tam 4 7 10
Tam?RT 1 1 2
Fyles et al. [6, 26] 1992–2000 611 (all T1 patients) Tam 5.5 13.8b N.A.
Tam?RT 0.4 5.3
114 (subset of G1/2, lum A patients) Tam 2c 4.9 N.A.
Tam?RT 5.5
Studies comparing hypofractionated 3-week EBRT versus 5-week EBRT
Whelan et al. [19] 1993–1996 1,234 3 week EBRT 2.33d 6.2 N.A.
5 week EBRT 2.17d 6.7
START-B 2008 1999–2001 2,215 3 week EBRT 2.2e NA NA
5 week EBRT 3.3e
Patient populations were largely postmenopausal women with node-negative, hormone-receptor-positive, early stage invasive breast cancer. Two
of the trials, Hughes et al. and Fyles et al., compared treatment regimens of XRT versus no XRT. The other two trials, Whelan et al. and START-
B, compared standard 5-week EBRT to hypofractionated 3-week EBRT
a 4-year follow-up data
b Includes ER-patients with a higher recurrence rate than ER ? patients
c The ER?/HER2-subset was presented at ASCO in 2002
d No significant difference between treatment groups
e Rates are for locoregional recurrence, not local recurrence
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mature. The chance that the results will change has a very
small probability, and practitioners could switch back to
EBRT, or switch to something that in the interim has been
shown to be better than EBRT. As our analysis indicates,
little will have been lost for any patient who receives
IORT, as many are also eligible for hormone therapy alone.
We have an opportunity to take an important step for-
ward in patient-centered care and to address the challenges
women face in returning for daily radiation treatments over
many weeks. It is reasonable to assume that patients would
prefer no radiation, IORT or shorter courses of EBRT even
simply on the basis of convenience. If women are con-
cerned only about distant recurrence, no radiation is the
appropriate treatment. If a 5–10 % difference in local
recurrence is important to avoid, IORT is an excellent
alternative to no radiation.
Having a robust method to ascertain the reliability of
results enables the community to move forward with
adopting new treatments, especially if we are confident that
they are safe. If they are also far less expensive, time and
resource-intensive, and could impact hundreds of thou-
sands of women in the US, Europe, and Australia, that
should be added incentive to drive adoption.
There is no point in putting the effort into funding and
conducting randomized clinical trials if at the end of the
process we feel uncomfortable making a change and
allowing new evidence to change our practice. It is rea-
sonable to question the results. However, we suggest that
rigor in evaluating the impact of trials can make a differ-
ence in the policy for adoption by looking at the likely
stability of results, the impact of early adoption if wrong
and the opportunity cost of late adoption.
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